VarmX

All Events Fund articles Fund PR Portfolio articles Portfolio PR

VarmX receives Phase 1 waiver from Japanese regulator PMDA

2025.09.252025.09.25 / for lead asset VMX-C001 Japanese regulator, the PMDA, waived the requirement for a Phase 1 trial in Japanese subjects for lead asset VMX-C001, enabling it to go straight to Phase 3 development ...

VarmX partners with CSL in a strategic collaboration and option agreement to develop novel investigational coagulation treatment

2025.09.162025.09.22 / Full funding of VMX-C001 Phase 3 trial, late-stage product development, manufacturing and pre-launch activities VarmX shareholders to receive initial $117m upfront and further potential milestone ...

VarmX receives IND approval for Phase 3 trial of VMX-C001 in Urgent Surgery

2025.07.092025.09.22 / Enables initiation of global EquilibriX-S trial later this year Critical milestone in development of novel bypass agent to restore coagulation, enabling urgent surgery in patients taking a ...

VarmX announces appointment of John Glasspool as CEO

2024.11.122025.04.30 / Leadership team fully strengthened to drive next phase of development Leiden, The Netherlands, 12 november 2024 VarmX, a biotech company developing innovative approaches for the bypass of direc ...

VarmX raises €30 million Series B2 financing for IND approvaland preparations for pivotal trial

2023.05.252024.05.13 / Sound Bioventures and EIC Fund join existing investors EQT Life Sciences (formerly LSP),Inkef, Lundbeckfonden BioCapital, Ysios Capital, BioGeneration Ventures, InnovationQuarter and Libertatis Ergo ...

From toxin to remedy, and operating room to the boardroom

2023.03.212024.09.11 / Even though it’s based on venom from one of the deadliest snakes in the world, the lead product of biotech startup VarmX can be life-saving for patients on blood thinners. It's an unexpected turn, bu ...